Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis - Top-Institutions - MDSpire

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis

  • By

  • Mengjiao Lu

  • Lei Yuan

  • Junjie Liu

  • Yifeng Dou

  • Jinguo Cui

  • July 15, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Emory University
    Emory University

    Atlanta, GA

    Key Differentiators

    • Oncology

  • #3

    University of Virginia
    University of Virginia

    Charlottesville, VA

    Key Differentiators

    • Oncology

  • #4

    Children’s Hospital Medical Center Cincinnati
    Children’s Hospital Medical Center Cincinnati

    Cincinnati, OH

    Key Differentiators

    • Oncology

  • #5

    South Texas Accelerated Research Therapeutics
    South Texas Accelerated Research Therapeutics

    San Antonio, TX

    Key Differentiators

    • Oncology

Original Source(s)

Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis

  • by Mengjiao Lu, Lei Yuan, Junjie Liu, Yifeng Dou, Jinguo Cui

  • July 15, 2026

Related Content

Risk factors for radiation pneumonitis following adjuvant radiotherapy for breast cancer: a retrospective cohort study

Potential profile analysis of return-to-work readiness and self-efficacy in postoperative breast cancer patients who have returned to work

A phase II clinical trial of neoadjuvant chemotherapy combined with immunotherapy and different radiotherapy fractionation regimens in HR+/HER2- breast cancer